Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm Phase 2 study of inhaled nemiralisib in APDS/PASLI
2015-004876-31Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemiralisib in Activated PI3Kδ syndrome (APDS) and Airways Infection, sponsored by GSK. Primary endpoint: Adverse events. Started Nov 2015; status: completed.
02
Drugs
nemiralisib
03
Conditions
Activated PI3Kδ syndrome (APDS)Airways Infection
Beyond the preview
Go deeper on 2015-004876-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004876-31.